MGMT promoter methylation testing by means of pyrosequencing fulfills the criteria of high clinical utility for predictive purposes in elderly glioblastoma and for prognostic purposes in all adult glioblastoma patients (Table 3). This evidence concerns the gene MGMT and glioblastoma.